Crossmark

Structure–activity relationship of 18F-labeled PD-L1-targeting small molecule ligands: impact of radiolabeling strategy on affinity and in vivo performance

Crossref DOI link: https://doi.org/10.1186/s41181-025-00359-2

Published Online: 2025-07-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Krutzek, Fabian

Donat, Cornelius K.

Stadlbauer, Sven https://orcid.org/0000-0003-2276-5330
Funding

Funding for this research was provided by:

ICPO Foundation (Grant number P26)

Helmholtz-Zentrum Dresden - Rossendorf e.V.
License Information

Text and Data Mining valid from 2025-07-01

Version of Record valid from 2025-07-01
More Information

Article History

Received: 5 May 2025

Accepted: 10 June 2025

First Online: 1 July 2025

Declarations

:

: Animal experiments were performed according to the guidelines of the German Regulations for Animal Welfare, approved by the Saxonian Ethical Committee for Animal Experiments (Reference Number DD25-5131/562/52).

: Not applicable.

: F.K. and S.S. have inventorship rights for the European patent applications EP21212444 (submitted on December 6th 2021) for biphenyl-based PD-L1-targeting agents in nuclear medicine, encompassing both imaging and therapeutic applications. No other potential conflicts of interest relevant to this article exist.

Document is current

Any future updates will be listed below